Nibulin®; From the coast of Japan sea to hands of clinicians

08 June, 2024

Eribulin, marketed as Nibulin® by NanoAlvand, represents a new ray of hope for patients battling metastatic breast cancer. Discovery of anti-cancer properties of halichondrin B, a substance found in a black sea sponge in the coast of Japan, led to the development of Eribulin.

Approved by the FDA, Eribulin offers a treatment option for women with metastatic breast cancer unresponsive to initial and subsequent treatments. Despite its challenging formulation due to its nature, NanoAlvand successfully make Eribulin solution for injection available to patients, ensuring access to this cutting-edge solution.

Super User

Apply for a Job Position

Curious about job opportunities?

© NanoAlvand. All rights reserved. Powered by ِDGN.